what compound is cagrilintide | C194H312N54O59S2 | CID 171397054 Cagrilintide + Semaglutide Blend |

A: Pramlintide requires multiple daily doses

Whether RegenesisMD can prescribe BPC-157 for any individual patient depends on current FDA guidance and the determination of a licensed compounding pharmacy at the time of prescription

[1] The more advanced regulatory activity belongs to the combination product CagriSema (cagrilintide plus semaglutide), which reached Phase 3 and for which a New Drug Application was reported to have been filed with the FDA in late 2025

Comparing the raw numbers as if they were a head-to-head duel manufactures a certainty the evidence does not support

Research-only note: Cagrilintide is not FDA-approved for therapeutic use

The most defensible reading is to treat each compounds own within-trial data as its evidence and to treat any cross-compound ranking as a hypothesis, not a result